IP Library Granted Patent US 7,927,676
Granted Patent B2
US 7,927,676 · App. 11/395,474 · Granted Apr 19, 2011

Plasma-treated vascular occlusion devices and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,927,676
App. No.
11/395,474
Granted
Apr 19, 2011
Kind
B2
Abstract

Vaso-occlusive devices are provided that have a polymer foam disposed about them. The polymer is treated with a plasma to facilitate thrombogenicity. A method for making and using such devices also is provided. The preferred polymer is a copolymer of a halogenated vinylidene and a halogenated alkene.

Claims (7)

1. A coated vaso-occlusive product comprising:

a vaso-occlusive device that is an embolic coil;

a polymer disposed about said vaso-occlusive device, the polymer being poly(vinylidene fluoride-co-hexafluoropropylene), a copolymer of vinylidene fluoride and hexafluoropropylene, and the ratio of vinylidene fluoride to hexafluoropropylene in the copolymer is 85:15;

the polymer is in the form of an open cell foam having voids between polymer domains, the polymer foam having been exposed to helium plasma gas at between about 50 and 200 millitorr; and

said polymer foam has a surface flourine composition of less than about 40% and has a surface oxygen composition of at least about 10%, while said polymer foam has a water contact angle of said polymer that has been decreased due to its having been exposed to helium plasma gas, the decreased water contact angle of said polymer being from about 35 to about 85 degrees.

2. The product of claim 1 , wherein said vaso-occlusive device is made from a material selected from platinum, nitinol, radio-opaque materials, and combinations thereof.

3. The product of claim 1 wherein said decreased water contact angle of said polymer persists for at least 60 days.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RE-RECORDING ASSIGNMENTS TO REMOVE INCORRECT DATA RECORDED ON 08/12/2009. PREVIOUSLY RECORDED ON REEL 023085 FRAME 0329. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER OF CORDIS DEVELOPMENT CORP. AND CORDIS NEUROVASCULAR, INC. INTO CODMAN & SHURTLEFF. Recorded Aug 3, 2010
From: CORDIS DEVELOPMENT CORPORATION; CORDIS NEUROVASCULAR, INC.
To: CODMAN & SHURTLEFF, INC.
Reel/Frame 024776/0472 →
MERGER Recorded Aug 12, 2009
From: CORDIS DEVELOPMENT CORPORATION; CORDIS NEUROVASCULAR, INC.
To: CORDIS NEUROVASCULAR, INC.; CODMAN & SHURTLEFF, INC.
Reel/Frame 023085/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2006
From: YANG, CHUNLIN; LI, YUFU; DO, HIEP; GOUNIS, MATTHEW; CHUN, IKSOO; DAVIS, III, RICHARD CHAMPION; SHERMAN, DARREN R.
To: CORDIS DEVELOPMENT CORPORATION
Reel/Frame 017684/0390 →